NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA
NCT03157128 2025-10-20LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 3 FDA
NCT02358031 2025-07-18MK-3475-048Merck Sharp & Dohme LLCPhase 3 Completed882 enrolled 50 charts 1 FDA
NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT03212404 2025-02-03Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersCheckpoint Therapeutics, Inc.Phase 1 Active not recruiting272 enrolled 1 FDA